Actively Recruiting
Innovating Access to Novel Therapies Through Standardized Prospective Integration of Response Evaluations (IMPACT-INSPIRE)
Led by National Cancer Centre, Singapore · Updated on 2026-05-13
50
Participants Needed
1
Research Sites
547 weeks
Total Duration
On this page
Sponsors
N
National Cancer Centre, Singapore
Lead Sponsor
S
SingHealth Duke-NUS Academic Medical Centre
Collaborating Sponsor
AI-Summary
What this Trial Is About
This observational study aims to assess the outcomes in patients with advanced treatment refractory cancers with matched molecular/precision therapy as per their molecular profiling results after discussion at molecular tumour board. 1. To standardize response assessment and data collection for patients that are receiving off-label or non-standard therapies based on MTB recommendations. \- Establish a standardized response assessment process and data collection patients that are receiving off-label or non-standard therapies based on MTB recommendations. 2. To demonstrate that it is feasible to standardize investigations and endpoints in this proof-of-concept study. * Through standard safety laboratory investigations (FBC, U/E/Cr, LFT) * Through standard radiological imaging at 6-12 weeks with the key endpoint being best response during that imaging window, and disease control rate at 6 months. Hypothesis: Our proposed IMPACT-INSPIRE study hypothesis is that standardised response assessment and data collection in patients with no available therapies receiving off-label systemic therapies, can provide a novel mechanism to assess oncological outcomes in this unique cohort of patients, generate hypothesis, and provide insights to future biomarker-driven drug development
CONDITIONS
Official Title
Innovating Access to Novel Therapies Through Standardized Prospective Integration of Response Evaluations (IMPACT-INSPIRE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 21 years or older
- Histologically or cytologically confirmed advanced solid tumors
- Have received and failed all standard anticancer therapies or are unsuitable for further standard treatment
- Able to understand and willing to provide written informed consent
You will not qualify if you...
- Contraindications to off-label or non-standard therapy as defined by the product label
- Other health conditions that may interfere with outcome assessment or study participation as judged by the clinician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Cancer Centre, Singapore
Singapore, Singapore, 168583
Actively Recruiting
Research Team
D
Daniel SW Tan, BSc(Hons), MBBS, MRCP, PhD
CONTACT
A
Aaron C Tan, MBBS, BSc(Med)Hons, PhD, FRACP
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here